ANTIMICROBIAL THERAPY FOR CHRONIC OSTEOMYELITIS IN ADULTS - ROLE OF THE QUINOLONES

Authors
Citation
Jp. Rissing, ANTIMICROBIAL THERAPY FOR CHRONIC OSTEOMYELITIS IN ADULTS - ROLE OF THE QUINOLONES, Clinical infectious diseases, 25(6), 1997, pp. 1327-1333
Citations number
49
Language
INGLESE
art.tipo
Article
ISSN journal
1058-4838
Volume
25
Issue
6
Year of publication
1997
Pages
1327 - 1333
Database
ISI
SICI code
1058-4838(1997)25:6<1327:ATFCOI>2.0.ZU;2-Q
Abstract
The development of antimicrobial therapy for osteomyelitis is reviewed . The disease, especially when chronic, is notoriously resistant to an tibiotic therapy. The duration of disease defining chronicity has decr eased considerably in the last 30 years. Successful therapy reflects i ncreased appreciation of the combined roles of surgical debridement an d prolonged antimicrobial courses. Parenteral high-dose beta-lactam ag ents yield clinical success for many patients with chronic osteomyelit is, particularly with prolonged administration and surgical debridemen t. Over the last decade, the initial success of oral quinolone therapy for gram-negative osteomyelitis was exploited further for staphylococ cal diseases. Open clinical trials and comparative trials suggest succ ess rates approximating those achieved with parenteral beta-lactams, p articularly with appropriate surgery and adequate duration of therapy. The early results with quinolones and rifampin for prosthesis-related infection are encouraging. Overall, oral quinolones provide a new and frequently proportionate response to a disease that is difficult to t reat.